Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination
therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of
chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable,
advanced/recurrent colorectal cancer.